Key clinical point: Lenvatinib/pembrolizumab shows promise in metastatic NSCLC.
Major finding: Overall response rate at 24 weeks was 33.3%.
Study details: Interim findings in 21 patients from a phase 1b/2 study.
Disclosures: Dr. Brose has received consulting fees, research grants, and honorarium from Eisai.
Brose M et al. SITC 2018, Abstract P392
This Week's Must Reads
Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.
Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.
Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.
Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.
Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.
Must Reads in Immuno-oncology
NEO-PV-01 vaccine shows good tolerability and safety , Hu-Lieskovan S et al. SITC 2018, Abstract 07.
Lenvatinib plus pembrolizumab shows promising activity in NSCLC, Brose M et al. SITC 2018, Abstract P392
NGS may ID SCLC candidates for immunotherapy, SITC 2018
Monalizumab + cetuximab is active in advanced SCC of the head and neck, Cohen R et al. SITC 2018, Abstract 051
Nivolumab boosts survival over chemo for advanced melanoma, Ascierto PA et al. JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514